Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the Iron Deficiency Injectable market grown in recent years?

In recent times, there has been a substantial growth in the market size of injectable treatments for iron deficiency. The market, which is predicted to increase from $14.06 billion in 2024 to $15.37 billion in 2025, is expected to grow at a compound annual growth rate (CAGR) of 9.3%. The rise during the historical period can be linked to the heightened prevalence of treatments for iron deficiency anemia, patients undergoing bariatric surgery, pediatric and adolescent patients, and increasing occurrences of pregnancy.

How is the iron deficiency injectable market size expected to evolve during the forecast period?

Expectations are high for a swift expansion in the iron deficiency injectable market in the forthcoming years. The market is set to swell to a valuation of $23.13 billion in 2029, rising at a compound annual growth rate (CAGR) of 10.8%. The anticipated growth during this time frame is largely due to factors such as an aging population, global healthcare strategies, governmental initiatives, increased treatments for chronic diseases, and quick replenishment of iron. Noteworthy trends predicted for this forecast period encompass advancements in iron formulations, the emergence of digital health solutions, progress in iron deficiency injection therapy, and a rise in the utilization of iron-based medications.

Get your iron deficiency injectable market report here!

https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report

Which key drivers are propelling the iron deficiency injectable market’s growth?

The rising occurrence of polycystic ovary syndrome (PCOS) is anticipated to accelerate the expansion of the iron deficiency injectables market in future. PCOS is a typical hormonal disorder impacting individuals with ovaries, mainly women at reproductive age. PCOS can cause iron overload, leading to significant blood loss during menstruation and resulting in anemia. This condition can be treated using iron deficiency injectable medications. For example, the World Health Organization, a specialized health agency in the US, reported in June 2023 that globally, an estimated 8–13% of women in reproductive age suffer from PCOS. Surprisingly, 70% of these cases remain undiagnosed. Hence, the growing prevalence of PCOS contributes to the development of the iron deficiency injectables market. The escalating rate of malnutrition plays a critical role in driving the expansion of the iron deficiency injectable market. Malnutrition is a health condition signifying an imbalance in the consumption and the body’s need for crucial nutrients. Iron deficiency injectables are given to malnourished patients to swiftly restore iron supplies in the body and deliver a concentrated dose of iron instantly absorbed into the bloodstream. This procedure allows for an immediate correction of the deficiency. According to records from the California Department of Public Health, a state-level governmental agency in the US, the mortality rate attributed to malnutrition escalated to 1,406 in 2022, marking a 22.36% increase against the 1,149 deaths reported in 2021. Consequently, the high malnutrition rate is expected to boost the iron deficiency injectable market’s growth in the future.

What are the market segments in the iron deficiency injectable industry?

The iron deficiency injectable market covered in this report is segmented –

1) By Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose

2) By Branded or Generics: Branded, Generics

3) By Application: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Applications

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Iron Sucrose: Venofer

3) By Ferric Carboxymaltose: Injectafer, Ferinject

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12907&type=smp

Which leading companies are shaping the growth of the iron deficiency injectable market?

Major companies operating in the iron deficiency injectable market are Daiichi Sankyo Company Limited, Pfizer Inc., Aetna Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A, AstraZeneca PLC, GSK PLC, Fresenius Medical Care, Teva Pharmaceutical Industries Ltd., Mylan N.V., B Braun Medical Inc., Sandoz, Fresenius Kabi AG, Cipla Limited, Emcure Pharmaceuticals Ltd., AMAG Pharmaceuticals Inc., Luitpold Pharmaceuticals Inc., Akebia Therapeutics Inc., Covis Pharma GmbH, Keryx Biopharmaceuticals Inc., Rockwell Medical Inc., American Regent Inc., Galen Medical Group.

What key trends are currently impacting the iron deficiency injectable market’s development?

Big players in the iron deficiency injectables market are pushing ahead with the development of new treatments, including INJECTAFER, to maintain their market dominance. For instance, in June 2023, American-based healthcare company, Daiichi Sankyo Company, together with injectables manufacturer, American Regent Inc., unveiled INJECTAFER (ferric carboxymaltose injection) specifically designed for iron deficiency, earning approval from the US government agency, the Food And Drug Administration. Remarkably, this is the inaugural intravenous iron replacement therapy for adults suffering from chronic and progressive heart failure to garner FDA approval. Over 40 different clinical trials were conducted with INJECTAFER, involving more than 8,800 participants worldwide. This latest FDA approval has further solidified INJECTAFER’s proven efficacy, particularly in adult and pediatric patients with iron-deficient anemia and heart failure.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12907

Which geographic areas are influencing the growth of the iron deficiency injectable market?

North America was the largest region in the iron deficiency injectable market in 2024. The regions covered in iron deficiency injectable market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Patient Blood Management Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/patient-blood-management-global-market-report

Hemoglobin Testing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/hemoglobin-testing-global-market-report

Stem Cell/Cord Blood Banking Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/stem-cell-cord-blood-banking-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: